Gauging the pharmaceutical burden on Sydney's environment: A preventative response

Journal of Cleaner Production

Volumn 11, Issue 3, 2003, Pages 315-320

  Fisher, Peter M J ^a   Borland, Robert ^b  

^a CENTRAL QUEENSLAND UNIVERSITY   (Australia)

^b Biodeim Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; EFFLUENT TREATMENT; GROUNDWATER POLLUTION; SEWAGE TREATMENT PLANTS; STRATEGIC PLANNING;

IMPACT REDUCTION STRATEGY;

ENVIRONMENTAL IMPACT;

EID: 0037400453     PISSN: 09596526     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-6526(02)00048-3     Document Type: Article

References (29)

1. Strong L., James S. Some effects of invermectin on the yellow dung fly, Scataphaga stericoraria. Vet. Parasit. 48:1993;181-191.
2. Hartmann A., Alder A.C., Koller T., Widmer R. Identification of flourochinolene antibiotics as the main source of umuC genotoxicity in hospital wastewater. Environ. Toxicol. Chem. 17:1988;377-382.
3. Alder Alfredo C., McCardell Crista S., Golet Eva M., Ibric Slavia, Molnar Evar, Nipales Norriel S., Giger Walter. Occurrence and fate of fluoroquinolene, macrolide, and sulfonamide antibiotics during wastewater treatment in ambient waters in Switzerland. Daughton C.G., Jones-Lepp T.L. Pharmaceuticals and personal care products in the environment: scientific & regulatory issues. 2001;Oxford University Press, Oxford.
4. Dollery C.T. Therapeutic drugs, Vol 1 & 2. 1991;Churchill Livingstone, Edinburgh.
5. ENDS 1999 Industry glimpses new challenges as endocrine science advances, No. 290, March 1999, pp. 26-30.
6. US EPA Pharmaceuticals and antiseptics: occurrence and fate in drinking water, sewage treatment facilities and coastal waters, EPA Grant Number R829004, 2001.
7. ENDS 2002 Leaking sewers threaten groundwater, No. 324, January 2002, p. 4.
8. Seiler Ralph L., Zaug Steven D., Thomas James M., Howcroft Darcy L. Caffeine and as indicators of wastewater contamination in wells. Ground Water. 17:(3, May-June):1999.
9. Rodgers-Gray T.P., Jobling S., Morris S., Kelly C., Kirby S., Janbakhsh A., Harries J.E., Walcock M.J., Sumpter J.P., Tyler C.R. Long term temporal changes in the estrogenic composition of treated sewage effluent and its biological effects on fish. Environmental Science & Technology. 34:2000;1521-1528.
10. Zuccato E., Bagnati R., Fioretti F., Natangelo M., Calamari D., Fanelli R.E. Environmental loads and detection of pharmaceuticals in Italy. Pharmaceuticals in the environment. 2001;19-27 Springer, New York.
11. Jensen John. Veterinary medicines and soil quality; The Danish situation as an example. Daughton C.G., Jones-Lepp T.L. Pharmaceuticals and personal care products in the environment: scientific & regulatory issues. 2001;Oxford University Press, Oxford.
12. ENDS 2000 A new focus on drugs in the environment, No. 304, May 2000, pp. 25-28.
13. Aycough N.J., Fawell J., Franklin G., Young W. Review of human pharmaceuticals in the environment, Environment Agency Report TRP 390, June 2000.
14. Commonwealth Department of Health & Community Service. Australian statistics on medicines - 1997, Department of Health & Community Services, Commonwealth of Australia, 1998.
15. Ternes Thomas. Pharmaceuticals and metabolites as contaminants of the aquatic environment. Daughton C.G., Jones-Lepp T.L. Pharmaceuticals and personal care products in the environment: scientific & regulatory issues. 2001;Oxford University Press, Oxford.
16. Daughton C.G. Illicit drugs in municipal sewage: proposed new non-intrusive tool to heighten public awareness of societal use of illicit/abused drugs and their potential for ecological consequences. Daughton C.G., Jones-Lepp T.L. Pharmaceuticals and personal care products in the environment: scientific & regulatory issues. 2001;Oxford University Press, Oxford.
17. Whitehouse M.W., Betts W.H., Macrides T.A. Anti-imflammatory activity of a lipd fraction (Lyprinol®) from the N.Z. green lipped mussel. Inflammopharmacology. 5:1997;237-246.
18. Sinclair AJ, Murphy KJ, Li D, Halpern GM, Sheils IA, Whitehouse MW, Dugas B. Marine lipids: overview: new insights and lipid composition of Lyprinol®; Allergie and Immunology; whole issue, Vol. XXXII, No 7, September 2000.
19. Emelyanov A., Fedoseev G., Krasnoschekova O., Abulimity A., Barnes P.J. Treatment of asthma with lipid extract of New Zealand green lipped mussel: a double blind, randomized, placebo controlled clinical trial. E. Respiratory J., accepted.
20. Scott R.E., Tzen C.Y., Witte M.M., Blatti S., Wang H. Regulation of differentiation, proliferation and cancer suppressor activity. Int. J. Dev. Biol. 37:1993;67.
21. Burr G.O., Burr M.M. On the nature and role of fatty acids essential in nutritio. J. Biol. Chem. 86:1963;587.
22. Bjerve K.S. Omega 3 fatty acid deficiency in man: implications for the requirement of alpha-linolenic acid and long-chain omega 3 fatty acids. World Rev. Nutr. Diet. 66:1991;133.
23. Bang H.O., Dyerberg J., Sinclair H.M. The composition of Eskimo food in north western Greenland. Lancet. 1:1143;1980.
24. Kuemmerer K., Al-Ahmed A., Bertram B., Wießler M. Biodegradability of antineoplastic compounds in screening tests: improvement by glucosidation and influence of stereo-chemistry. Chemosphere. 40:2000;763-767.
25. Fisher Peter M.J. Medicating our environment. Australian Financial Review. 9:(June):2000;6-7.
26. Ungemach F.R. Figures on quantities of antibacterials used for different purposes in the EU countries and interpretation. Acta Vet. Scan. 2000; 93: 97-98.
27. Ranga Velagaleti, Michael Michael Gill. Regulatory oversight for the environmental assessment of human and animal health drugs: environmental assessment for drugs. Daughton C.G., Jones-Lepp T.L. Pharmaceuticals and personal care products in the environment: scientific & regulatory issues. 2001;Oxford University Press, Oxford.
28. Montforts M.H.M.M. Regulatory and medical aspects concerning the risk assessment for medicinal products: need for research. Pharmaceuticals in the Environment. 2001;Springer, New York.
29. EMEA. Note for the guidance of environmental risk assessment for veterinary medicinal products other than GMO-containing and immunological products, European Agency for the Evaluation of Medicinal Products, Committee for Veterinary Medicinal Products, (EMEA/CVMP/055/96, 1997.